drugset

drugset / Trial / NCT05254912

Photoallergic Potential of 6% Bemotrizinol

NCT05254912 ↗

Phase 2 Completed 50 enrolled dsm-firmenich Switzerland AG

Non-randomizedFactorialSingle-blindBasic science

Summary

This clinical trial will assess the photoallergic potential of BEMT (6%), compared to a vehicle control and a negative control.

Timeline

Start: 2022-03-07
Primary completion: 2022-04-22
Completion: 2022-04-22

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Bemotrizinol	Unknown	6 %	Topical

Indications